India’s stakes in the Global Pandemic Agreement

1. At a Glance

• The WHO Pandemic Agreement (PA) is the first global legal instrument focused on pandemic prevention, preparedness and response (PPPR). The World Health Assembly (WHA) adopted it on 20 May 2025 through resolution WHA78.1 [2].
• It is the second legally binding health treaty negotiated under WHO, after the WHO Framework Convention on Tobacco Control (2003). (This background is not backed by any retrieved source. Verify it before use.)
• India voted for the PA, along with 123 other member-states. No country voted against, and 11 abstained [1].
• The PA's most important operational part is still unfinished. The Pathogen Access and Benefit-Sharing (PABS) annex is being negotiated by an Intergovernmental Working Group (IGWG), so the PA is not yet open for ratification [1][2].
• Why UPSC cares: the topic covers the North–South split in global health, equitable access to vaccines, India's role as a vaccine manufacturer and voice of the Global South, One Health, and the balance between national sovereignty and international obligations (GS-II).

2. Why in the News

• September 2026: India made official remarks on the Political Declaration on PPPR at the UN High-Level Meeting (UN HLM) in New York [1].
• 18 September 2026: WHO member states finished the 8th IGWG meeting and advanced PABS negotiations ahead of the UN General Assembly meeting on pandemics [5].
• 8 October 2026: an op-ed in The Hindu by Priyadarshini Singh (Research Fellow, Centre for Social and Economic Progress, CSEP) argued that India's leadership can help bridge the divides in global pandemic governance [1].

3. Background & Evolution

• Rationale: COVID-19 showed deep inequity in access to vaccines, medicines and diagnostics. The negotiations then turned on how to balance national sovereignty with international cooperation and solidarity [1].
• Milestones:
• 20 May 2025: the 78th WHA adopts the PA through WHA78.1 [2].
• 20 May 2025: the same resolution sets up the IGWG to draft and negotiate the PABS annex under Article 12 of the PA. The IGWG reports to the 79th WHA [2][3].
• July 2025: the IGWG holds its first meeting and agrees on next steps [3].
• January 2026: the IGWG holds a resumed fourth meeting [6].
• February 2026: member states continue negotiating the "key annex", which WHO describes as a sign of global commitment [4].

• September 2026: the 8th IGWG meeting concludes [5], and the UN HLM adopts a Political Declaration on PPPR [1].

• Why PABS was deferred: it was too technically and politically complex to settle in the main negotiations. To stop the talks from collapsing, member states adopted the core text and moved PABS into a separate annex [7].

4. Core Static Facts

5. Multi-Dimensional Analysis

Geopolitical / Strategic

• The negotiations exposed Global North vs Global South fault lines over sovereignty, financing and access [1].
• Adoption without a single vote against shows that high-, middle- and low-income countries broadly agree on the framework [1].
• India can act as a bridge between developed and developing countries in pandemic governance [1].

Economic

• A contested question is whether private manufacturers can be required to share vaccines in real time at affordable prices [1]. India's large generic-drug and vaccine industry has a direct interest in the answer.
• Another is whether binding targets, such as One Health obligations, are fair when funding is not guaranteed for countries with fragile health systems [1].

Legal / Governance

• Even without ratification, the PA creates a first-of-its-kind global legal framework for pandemics [1].
• Can national pandemic regulations be harmonised through global frameworks? This tests sovereignty limits [1].
• PABS is to be legally binding but sits in an annex, which makes the treaty a two-step process [2][7].

Social / Equity

• PABS aims at fair, equitable access to countermeasures for LICs and LMICs [1]. This responds to the vaccine inequity seen during COVID-19.

Scientific / Technological

• PABS ties the sharing of pathogen samples and data to benefit-sharing: vaccines, therapeutics and diagnostics [1][2].
• The One Health approach links human, animal and environmental health in pandemic prevention [1].

6. Recent Developments (last 12–18 months)

• 10 July 2025: the first IGWG meeting agrees next steps on key PA elements [3].
• 20 January 2026: the resumed fourth IGWG meeting is held [6].
• 17 February 2026: countries negotiate the key PABS annex [4].
• 18 September 2026: the 8th IGWG meeting concludes with progress on PABS, ahead of the UNGA pandemic meeting [5].
• September 2026: the UN HLM in New York takes up the Political Declaration on PPPR, and India makes official remarks [1].

7. Prelims Hooks

• The WHO Pandemic Agreement was adopted on 20 May 2025 [2].
• The adopting resolution is WHA78.1, at the 78th World Health Assembly [2].
• Vote: 124 for, 0 against, 11 abstentions. India voted for [1].
• PABS stands for Pathogen Access and Benefit-Sharing [1].
• PABS falls under Article 12 of the Pandemic Agreement [2].
• PABS is negotiated by the Intergovernmental Working Group (IGWG), not the earlier treaty-negotiating body [2][3].
• The IGWG must submit its outcome to the 79th WHA [2].
• The PA is not yet open for ratification while the PABS annex is pending [1].
• The 8th IGWG meeting concluded in September 2026 [5].
• The Political Declaration on PPPR came out of the UN High-Level Meeting in New York, September 2026. It is a UN document, not a WHO one [1].
• One Health is one of the contested measures in the PA [1].

8. Why the 20% Vaccine Promise Depends on Who Signs Up

• The 20% rule binds only companies that choose to join
• Under Article 12.6, each "participating manufacturer" must make available to WHO 20% of its real-time production (what it makes while the pandemic is going on) of vaccines, therapeutics and diagnostics [2].
• The treaty does not define "participating manufacturer". That is left to the PABS annex, which is still being negotiated [2].

• So the most important number in the treaty applies only to firms that join, and joining is not yet defined.

• Only half of the 20% is free

• The guaranteed minimum is 10% of real-time production, given as a donation [2].
• The rest goes to WHO at "affordable prices", with "flexibility based on the nature and capacity of each participating manufacturer" [2].

• Neither "affordable" nor "flexibility" has a fixed meaning yet. Each will be settled in separate contracts between WHO and each company [2].

• The guarantee covers only the most serious stage of an outbreak

• The 20% duty starts only when a pandemic emergency is declared. That is the top alert level, above a PHEIC (public health emergency of international concern) [2].
• At the PHEIC stage, the annex has to include only "options" for access, not a fixed share [2].
• In the early weeks, when doses are scarcest, there is no fixed share at all.

9. Why Technology Transfer Stays Optional

• One footnote turns a duty into a choice
• Articles 4, 11 and 17 promote transfer of technology "as mutually agreed" [2].
• Footnote 8 explains that phrase as "willingly undertaken and on mutually agreed terms" [2].

• So no company can be required to share its vaccine know-how. Countries of the Global South wanted sharing to be mandatory. The final text makes it voluntary.

• Governments only "encourage" patent holders

• Article 11.1(d) asks Parties to encourage patent holders to waive royalties (fees paid to use a patent) or keep them reasonable during a pandemic [2].

• Most vaccine patents belong to private firms in rich countries. A request to "encourage" does not oblige them to do anything.

• TRIPS flexibilities are confirmed, not expanded

• Article 11.4 reaffirms the right to use the TRIPS Agreement (the WTO's rules on intellectual property) and the 2001 Doha Declaration (which says public health can override patents) [2].
• But Parties must use these flexibilities only in ways "consistent with" TRIPS [2]. The treaty adds no new tool beyond what the COVID-era TRIPS waiver debate was already about.

10. Duties Without Guaranteed Money

• The One Health and prevention duties have an escape clause
• One Health means treating human, animal and environmental health as linked. Under Article 5, countries take One Health measures "subject to the availability of resources" [2].
• Article 4 on prevention plans uses the same words [2].

• A country that does nothing can simply say it had no funds. This is the fairness concern the note raises, but written into the treaty itself.

• Financing is promised only "to the extent feasible"

• Article 18 asks Parties to strengthen financing "to the extent feasible" [2].
• It sets no assessed contribution, meaning no fixed share that each country must pay.
• The Coordinating Financial Mechanism is not a new fund. It reuses the mechanism already set up under the IHR (2005), the International Health Regulations [2].

• Its rules have to be agreed only within 12 months after the treaty comes into force [2].

• No penalty for breaking the rules

• Article 19.6 says the compliance body will be "non-adversarial, non-punitive" and can make only non-binding recommendations [2].
• A country that ignores its duties faces no penalty.

11. Why the Treaty Is Still Years Away

• No country can even sign yet
• Article 31.2 says the treaty opens for signature only after the WHA adopts the PABS annex [2].

• So the delay in IGWG talks is not a side issue. It holds back the whole treaty.

• After the annex is adopted, the treaty still has to clear three more steps

• It needs 60 ratifications. It then enters into force 30 days after the 60th one (Article 33) [2].
• The first Conference of the Parties (COP, the meeting of countries that have joined) must be held within one year of entry into force (Article 19.3) [2].
• The financing rules come within 12 months after that [2].
• A new pathogen will not wait for these steps. A pandemic in this gap would be handled under the IHR (2005) and voluntary deals, as COVID-19 was.

12. The Sovereignty Fear, and What It Gets Right

• The objection: a WHO treaty lets Geneva override national decisions on lockdowns, vaccine mandates or borders. Some of the 11 abstentions [1] reflect this worry.
• The text says the opposite
• Article 22.2 says WHO, including its Director-General, has no authority to direct national law, or to order travel bans, vaccine mandates or lockdowns [2].
• Article 3.1 makes "the sovereign right of States" to legislate the first guiding principle [2].

• Article 25 allows reservations, which let a country opt out of parts of the treaty, unless they defeat its purpose [2].

• What the objection gets right, the other way round

• The same protections that keep sovereignty safe also make the treaty weak.
• No enforcement, voluntary technology transfer and duties that depend on funds mean the PA cannot make any country, rich or poor, behave differently in the next crisis.
• In real terms, the sovereignty debate ended in a treaty that depends on good faith. Equity now rests almost wholly on how strong the PABS contracts turn out to be.

13. What India Gives and What India Gets

• India gets two things from the treaty, and gives up two
• Gains:
  • PABS must be built "to facilitate the manufacture and export" of vaccines and diagnostics (Article 12.5(f)) [2]. That suits a country that makes vaccines for export.
  • Article 10 backs geographically diversified production (factories spread across regions, not just in rich countries) in developing countries [2]. This is where Indian firms are strong.

• Concessions:

  • If Indian manufacturers join PABS, they too must give WHO 20% of their output during a pandemic [2]. That limits how freely the government and companies can supply Indian buyers first.
  • Article 12.5(d)(ii) asks every Party to align its national ABS (access and benefit-sharing) rules with the PABS annex. National rules that conflict will stop applying for pathogens it covers [2].

• India shares samples and also receives benefits

• India supplies pathogen samples and gene sequence data, and it also produces vaccines. So it gains from strong benefit-sharing and from light rules on manufacturers.
• This mixed position is why the op-ed sees India as a possible bridge between North and South [1]. It is also why India's negotiators have to choose which of its interests to put first in the annex.

14. Lessons from the 2011 Flu Deal

• PABS has a working model: the PIP Framework
• The 64th WHA adopted the Pandemic Influenza Preparedness (PIP) Framework unanimously on 24 May 2011 [8].
• It links the sharing of flu viruses to wider access to vaccines for developing countries [8].

• It works through Standard Material Transfer Agreements (SMTAs), which are fixed contracts with each company. PABS also plans to use contracts signed with WHO [8][2].

• PABS must fit alongside PIP, not replace it

• Article 12.5(d)(i) says PABS must be "complementary to, and not duplicative of" PIP [2].

• PIP covers only influenza. PABS has to cover all pathogens with pandemic potential, including new viruses like the one behind COVID-19.

• What the IGWG and India should take from PIP

• Set the contract terms in advance: PIP fixes company duties through standard contracts signed before a crisis [8]. India should push for a single standard PABS contract, so that "affordable price" and "flexibility" are settled before an outbreak and not argued over during one.
• Make joining the condition for using shared data: India should push for a definition of "participating manufacturer" that makes PABS terms a condition of using the shared samples and sequence data. Otherwise the 20% rule will be easy to avoid [2].

15. Anchors for Answers

• Data: 20% of real-time pandemic production to WHO, of which at least 10% is donated (Article 12.6, WHO Pandemic Agreement) [2]
• Data: the treaty enters into force 30 days after the 60th ratification, and opens for signature only after the PABS annex is adopted (Articles 31, 33) [2]
• Law/Case: Article 22.2 of the PA says WHO cannot order lockdowns, vaccine mandates or travel bans [2]; Article 11.4 reaffirms the TRIPS Agreement and the 2001 Doha Declaration [2]
• Comparison: PIP Framework (2011, influenza only): virus sharing tied to vaccine access through fixed standard contracts, the model PABS must complement [8]
• Report/Committee: Intergovernmental Working Group (IGWG) under resolution WHA78.1, reporting to the 79th WHA [2]

16. Mains Relevance

• GS-II: important international institutions and agencies (WHO, UNGA); bilateral, regional and global groupings affecting India's interests; issues relating to the health sector.
• GS-III: science and technology (vaccines, pathogen genomics); IPR issues.
• Possible questions: 1. The WHO Pandemic Agreement reflects the tension between national sovereignty and global solidarity. Critically examine, highlighting India's stakes. (250 words) 2. Discuss the significance of the Pathogen Access and Benefit-Sharing (PABS) system for equitable access to medical countermeasures. How can India shape its outcome? (150 words) 3. Lessons from COVID-19 have reshaped global health governance. Evaluate the role India can play in bridging Global North–South divides in pandemic preparedness. (250 words)

17. Related Topics to Study Next

• International Health Regulations (IHR, 2005) and their amendments: these sit alongside the PA in the global legal regime on pandemics.
• One Health approach: a contested obligation in the PA, and relevant to India's zoonotic disease programmes.
• Nagoya Protocol (CBD) on access and benefit-sharing: the conceptual parent of PABS.
• TRIPS waiver debate at the WTO (COVID-19): the IPR side of vaccine equity.
• Vaccine Maitri and COVAX: India's past vaccine diplomacy and the multilateral access model.
• WHO Pandemic Influenza Preparedness (PIP) Framework: an earlier pathogen-sharing model to compare with PABS.
• Global South leadership (Voice of Global South Summits, G20 health track): the platforms for India's bridging role.

18. NCERT Concepts to Revise

• Nagoya Protocol (Geography): Conceptual parent of PABS: it governs access to genetic resources and fair sharing of benefits.
• Access and benefit sharing (Economy): PABS applies this principle: countries sharing pathogen samples and data get a share of vaccines and therapeutics.
• Sovereignty (Polity): The treaty debate balances national sovereignty against binding international obligations and global solidarity.
• Intellectual property rights (Economy): Whether private manufacturers must share vaccine know-how at affordable prices is an IPR question.
• TRIPS (Economy): The COVID-19 TRIPS waiver debate at the WTO is the IPR side of vaccine equity.
• Convention on Biological Diversity (Geography): The CBD is the parent treaty of the Nagoya Protocol, which inspired PABS.

19. Common Errors / Trap Areas

• WHA vs UNGA: the PA was adopted by the WHA (WHO) in 2025 [2]. The Political Declaration on PPPR comes from the UN HLM in 2026 [1].
• Adopted vs in force: the PA is adopted but not yet open for ratification, because of the pending PABS annex [1].
• Vote numbers: 124 for and 11 abstentions, with zero against [1]. Don't mix up abstentions with votes against.
• IGWG vs the treaty-negotiating body: the IGWG was created by WHA78.1 specifically for the PABS annex [2].
• The PA vs IHR amendments: these are separate instruments. Don't treat them as the same thing.